report
New first-in-class therapies for 2022
View the Q1 2022 OptumRx Drug Pipeline Insights Report.
Every new year brings new drug approvals. Following the theme of our previous OptumRx Drug Insights Report, we analyze three new drugs with an expected FDA decision by the end of the first quarter of 2022.
In this latest quarterly Drug Pipeline Insights Report, OptumRx reviews several potential first-in-class therapies, including those for:
- Severe asthma
- Long-acting prevention of HIV in at-risk individuals
- Anemia associated with chronic kidney disease
Don't want to read the full report? Download the brief summary.
Top